Core Viewpoint - The company is focusing on both endogenous growth and external expansion to achieve sustainable development, leveraging its core product and exploring innovative drug frontiers through strategic investments [1][5]. Internal Growth - The company has established a comprehensive industrial layout covering Tibet, Sichuan, Shanghai, and overseas markets over the past two decades [6]. - Its product range includes biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, with key products addressing cardiovascular, liver, and respiratory issues [6]. - The core product, Xinhuasuan, is a self-developed national biological product for treating acute heart failure, which has maintained stable sales revenue [6]. - The company plans to invest several million yuan in evidence-based medical exploratory research for Xinhuasuan to expand its application scenarios and enhance academic promotion [6]. - Xinhuasuan has reached nearly 7,000 medical institutions, with plans to strengthen partnerships with commercial companies to further expand its coverage [6][7]. External Expansion - The company is investing in the cutting-edge field of gene editing, having invested $60 million in Accuredit Therapeutics Limited, acquiring a 40.82% stake [8][9]. - Accuredit focuses on developing in vivo gene editing technologies and products, aiming to provide innovative treatment solutions with cost advantages [9]. - The company also invested $30 million in Jiangsu Chentai Pharmaceutical Technology Co., acquiring a 13.04% stake, with Chentai's Zorifertinib being a significant product for advanced non-small cell lung cancer [10]. Future Strategy - The company aims to enhance its innovation platform to support cutting-edge innovation and increase its product pipeline, focusing on both internal and external growth strategies [11]. - Future efforts will include increasing R&D investment and project introduction, driven by new media marketing and innovative drug development to improve profitability and sustainable growth [11].
董事长专访 | “内外”兼修 西藏药业转型谋新篇